Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin

Joop E Arends*, Justin H Fransen, Andy I M Hoepelman, Debbie van Baarle

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)


Host polymorphisms in the IL28B region have recently been associated with outcome of treatment for hepatitis C virus (HCV) infection. This study clearly shows an association between first-phase viral load decrease and the IL28B rs12979860 polymorphism in chronic HCV-infected patients. Furthermore, a higher treatment efficiency factor (ɛ) was found in those HCV-infected patients with a CC genotype compared with those with a CT and TT genotype. This study highlights the importance of host response mechanisms in relation to favourable clearance of HCV.

Original languageEnglish
Pages (from-to)538-539
Number of pages2
JournalInternational journal of antimicrobial agents
Issue number6
Publication statusPublished - Dec-2011
Externally publishedYes


  • Antiviral Agents/therapeutic use
  • Hepacivirus/drug effects
  • Hepatitis C, Chronic/drug therapy
  • Humans
  • Interferon alpha-2
  • Interferon-alpha/therapeutic use
  • Interferons
  • Interleukins/genetics
  • Polyethylene Glycols/therapeutic use
  • Polymorphism, Single Nucleotide/genetics
  • Recombinant Proteins/therapeutic use
  • Ribavirin/therapeutic use
  • Treatment Outcome
  • Viral Load/drug effects

Cite this